Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01190475 · ClinicalTrials.gov registry record · Phase 2
BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
A Phase 2 study of Endometriosis, sponsored by Mereo BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01190475: Completed Phase 2 study of Endometriosis, sponsored by Mereo BioPharma.
NCT01190475 is a Phase 2 study of Endometriosis that has completed, run by Mereo BioPharma. The registered enrollment target is 6 participants, below the 264-participant average among 48 other Endometriosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01190475, a Phase 2 study of Endometriosis, has completed, sponsored by Mereo BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.
Primary Outcome
Proportion of patients who develop 2 or more follicles with diameter 16 mm or larger.
Conditions Studied
Interventions
- DRUG Active treatment with a high dose of BGS649
- DRUG Active treatment with a low dose of BGS649
- DRUG Placebo treatment to blind study
Study Locations (1)
California
- Novartis Investigative Site - Anaheim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT01190475 record still lists
NCT01190475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 264-participant average among 48 other Endometriosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 3 interventions - of which Active treatment with a high dose of BGS649 is the first listed.
NCT01190475 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01190475 about?
NCT01190475 is a clinical study titled "BGS649 Monotherapy in Moderate to Severe Endometriosis Patients". This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.
What is the current status of trial NCT01190475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2010-07. Estimated completion is 2011-09.
What conditions does trial NCT01190475 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT01190475?
The interventions under investigation include: Active treatment with a high dose of BGS649 (DRUG), Active treatment with a low dose of BGS649 (DRUG), Placebo treatment to blind study (DRUG).
Who is sponsoring clinical trial NCT01190475?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01190475 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01190475's enrollment target sits among peer trials
6 49th of 48 the lowest of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
COMPLETED · Phase 2
-
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia